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Abstract: Background: For patients with malignant pleural mesothelioma (MPM), a multimodality treat-
ment concept including neoadjuvant chemotherapy and radical surgery offers improved overall survival.
While the lung-sparing extended pleurectomy and decortication (EPD) has become the preferential sur-
gical approach, the more aggressive extrapleural pneumonectomy (EPP) remains reserved for a selected
group of patients. Based on our experience from the past two decades, we aim to discuss and assess
today’s role of EPP. Methods: Out of 523 MPM patients intended to be treated by induction chemother-
apy followed by macroscopic complete resection between January 1999 and December 2019, we identified
151 consecutive patients who underwent EPP at our center. All patients were treated within a mul-
timodality concept including neoadjuvant chemotherapy with platinum-based agents plus gemcitabine
or pemetrexed. Clinical data were collected in an online database and analyzed retrospectively. Re-
sults: Of all patients, 57.6% were of IMIG stage IA or IB (n=87), 39.0% of all patients IMIG stage
IIIA or IIIB (n=59). Mean tumor volume after induction chemotherapy was 294.6±315.0 cm3. Most
patients were operated in the first decade between 1999 and 2009 [112 patients (74.2%)]. The overall 30-
and 90-day mortality was 4.6% and 10.6%, respectively. The median overall survival was 18.5 months.
Major postoperative morbidity was assessed as a composite outcome and occurred in 38.4% of all pa-
tients. Conclusions: Although EPD became the procedure of first choice, EPP is a reasonable approach
in selected patients with high tumor burden and extensive involvement of the lung parenchyma, where
parenchyma-sparing resection is technically not feasible or functionally not rational. All patients should
be preoperatively assessed and informed about the eventuality of EPP, depending on intraoperative find-
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Introduction
Malignant pleural mesothelioma (MPM) is a very 
aggressive malignancy with a poor prognosis, requiring 
a complex treatment. Despite the fact that asbestos, the 
main etiologic factor, has been banned in most industrial 
countries for several decades, its global incidence is still 
increasing and MPM is expected to become a significant 
problem in third world countries in the next decades (1). 
In an adequately selected group of patients with resectable 
disease, a multimodality approach including neoadjuvant 
chemotherapy with platinum and anti-folate doublet, 
followed by surgical resection is part of the most recent 
guidelines (2-5). Due to the tumor’s anatomical restraint 
with proximity to the heart and the big vessels, the chest 
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wall and the diaphragm, extensive resection is often not 
possible and microscopic tumor will eventually be left 
behind. The aim of a radical surgical treatment is therefore 
to achieve macroscopic complete resection (MCR) (4,6). 
MCR can be obtained by both extrapleural pneumonectomy 
(EPP) or extended pleurectomy and decortication (EPD). 
While EPP includes an en-bloc resection of the parietal 
pleura, the lung, the pericardium and the ipsilateral 
diaphragm, EPD forms a lung-sparing approach where 
only parietal and visceral pleura, the pericardium and the 
ipsilateral diaphragm are resected. An isolated pleurectomy 
and decortication (PD) can be evaluated in selected 
patients with no macroscopic or histological signs of tumor 
infiltration into the pericardium or diaphragm.
While EPP had already been established for treatment 
refractory tuberculosis in 1949 (7), EPP for MPM was only 
introduced in a series of 29 patients by Butchart et al. in 
1976 (8). While in these patients, in-hospital mortality was 
as high as 31%, the safety of this procedure significantly 
improved over the following decades with short-term 
mortality ranging between 2.2% and 8.0% in recent 
reports (3,9-12). The technique of EPP has been described 
in previous articles and is largely consistent, including 
an extended lateral thoracotomy, extrapleural dissection 
of the tumor, as well as resection and reconstruction 
of the pericardium and the diaphragm (10). Increasing 
evidence from a number of retrospective cohort studies 
has demonstrated similar overall survival in EPP and 
EPD. Since EPP has been shown to be associated with a 
higher short-term mortality and morbidity, most centers 
have established EPD as a standard of care (3,12-14). The 
spared lung parenchyma and ideally preserved functional 
reserve after EPD results in improved quality of life and 
better tolerance towards further treatment (15). However, 
also in EPD the management of prolonged air leak and 
postoperative infections of the pleural cavity remain a 
challenge. 
In this present article we aim to assess and discuss today’s 
role of EPP after induction chemotherapy followed by 
MCR, based on our own 20-year experience. We present the 
following article in accordance with the STROBE reporting 
checklist (available at http://dx.doi.org/10.21037/shc-20-64).
Methods
Out of 523 patients with the diagnosis of MPM who 
underwent surgical resection within a multimodality concept 
at the Department of Thoracic Surgery of the University 
Hospital Zurich between January 1999 and December 
2019, we identified 151 patients who underwent EPP. In 
all patients included in this study, the diagnosis of MPM 
had been histopathologically confirmed and a clinical T1–3 
N0–2 M0 stage was present. A predicted postoperative 
forced expiratory volume in 1 second (FEV1) >1 L or >40% 
based on the preoperative spirometry was required for EPP. 
Perfusion was assessed routinely by ventilation/perfusion 
(V/Q) scan. In all cases, surgery was performed within a 
multimodality approach following three or four cycles of 
neoadjuvant chemotherapy with platinum-based agents and 
gemcitabine or pemetrexed. The combination of cisplatin 
and pemetrexed was used as a standard after improved 
survival rates had been shown in a randomized phase III trial 
in 2003 (16). In order to identify patients who will benefit 
from a multimodality approach, a multimodality prognostic 
score (MMPS) was established at our institution and has 
been shown to serve as an independent prognosticator 
for overall survival (OS) (17). In patients with an MMPS 
of 3 or 4 after neoadjuvant chemotherapy, the OS is not 
prolonged by subsequent radical surgery. The MMPS was 
therefore routinely assessed before surgical resection since 
its establishment in 2015. An approval of the local ethics 
committee was obtained for the retrospective analysis of the 
mesothelioma data base (StV 29-2009, EK-ZH 2012-0094). 
Study endpoints
We aimed to assess perioperative mortality (in-hospital 
mortality, 30-day mortality, 90-day mortality), postoperative 
major morbidity and OS in our patient cohort. Major 
morbidity was defined as a composite outcome combining 
postoperative hemorrhage requiring surgery, a failure of the 
diaphragmatic or pericardial patch and/or diaphragmatic 
hernia, chylothorax, pleural empyema, bronchopleural 
fistula (BPF), acute respiratory distress syndrome (ARDS) 
and pulmonary embolism. For baseline characteristics of 
our cohort we collected data on gender, age, body mass 
index (BMI), preoperative lung function [FEV1, forced 
vital capacity exhaled (FVCex), diffusion capacity of carbon 
monoxide (DLCO)], smoking status, exposure to asbestos, 
MPM histology, the MMPS and neoadjuvant chemotherapy. 
The response to induction chemotherapy was evaluated by 
the modified response evaluation criteria in solid tumors 
(RECIST) and assessed using a dedicated reading workstation 
(Impax 5.2, AGFA, Bonn, Germany). The PET-CT scans 
before and after chemotherapy were linked at the identical 
anatomical position and tumor thickness was measured 
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at three different levels in two distinct positions (18). 
MPM staging data are based on the TNM 8th edition [2016]. 
Mean tumor volume pre and post chemotherapy were 
assessed based on the staging positron emission computed 
tomography (PET-CT). During the reported 20 years, the 
diagnostic workup has changed and data on tumor volume, 
RECIST and the MMPS are therefore only available in 
more recent cases. The study population also included 52 
patients who were included in the SAKK 17/04 randomized 
phase 2 trial (19). Of our cohort, 16 patients were included 
in the intervention arm and had received additional adjuvant 
high-dose hemithoracic radiotherapy.
Surgical technique
EPP was performed as a standardized procedure defined by 
an en-bloc resection of the parietal pleura and the lung via 
an extended lateral thoracotomy in the 6th intercostal space, 
as described previously (20). Using blunt force, the parietal 
pleura was dissected from the endothoracic fascia. In case 
of localized chest wall infiltration, the affected region of 
the chest wall was further excised. The parietal pleura was 
dissected from the thoracotomy towards the hilum. The 
pericardium or the diaphragm were resected if macroscopic 
or microscopic (confirmed by fresh frozen sections) 
infiltrations were present. Subsequently, the pulmonary 
ligament was divided and the hilum was approached. The 
pulmonary artery, as well as the superior and inferior 
pulmonary veins were divided intrapericardially and the 
main stem bronchus was closed using stapling devices. For 
reconstruction of the pericardium, an acellular biological 
patch was used and for reconstruction of the diaphragm, 
a Gore-Tex biomaterial patch was put in place and fixed 
to the chest wall. A systematic lymphadenectomy of the 
mediastinal lymph nodes was performed according to lung 
cancer surgery (right side: ATS 2R, 4R, 7, 10R; left side: 
ATS 5, 6, 7, 10L). If applicable, internal mammary artery 
nodes and intercostal nodes were resected as well.
Statistical analysis
Continuous variables are reported as mean ± standard 
deviation for normally distributed data and median with 
95% confidence interval (CI) for non-normal distributions. 
Categorical variables are expressed as frequencies and 
percentages. Outcomes of the first and the second decade 
were compared using the unpaired t-test for continuous 
variables and using the Chi2-Pearson-test for categorical 
variables. Missing data (as well as loss to follow-up) was 
addressed by available case analysis. The 1-, 2-, and 3-year 
survival rates, as well as median OS were assessed by 
Kaplan-Meier curves. Statistical analysis was performed in 
IBM SPSS Statistics Version 24 (SPSS Inc, Chicago, IL).
Results
Baseline profiles
The baseline clinical profile of all 151 patients undergoing 
EPP for MPM is presented in Table 1. Of all patients, 87.4% 
were male and the mean age at the time of the operation 
was 60.0 years. Epitheloid MPM was the most commonly 
found histotype (63.6%), followed by biphasic (32.5%) 
and sarcomatoid (2.0%) histotype. After neoadjuvant 
chemotherapy, a partial remission was seen in 36.9% of all 
patients, whereas 37.9% showed a stable disease and 25.2% 
a progressive disease. At the time of re-staging by PET-CT 
after neoadjuvant chemotherapy, mean tumor volume was 
294 cm3. The most common International Mesothelioma 
Interest Group (IMIG) stage was IB (50.3%), followed by 
stage IIIA (25.8%).  Adjuvant radiotherapy was performed 
in 48.3% of all patients (n=73). Of these patients, 16 were 
included in the intervention arm of the SAKK 17/04 phase 
2 trial and received adjuvant high-dose radiotherapy of 
the entire hemithorax and mediastinal nodal stations (19) 
and 52 patients were described previously in a propensity-
matched comparison of EPP and EPD (12). Most patients 
were operated in the first decade between 1999 and 2009 
(1st decade: 112 patients (74.2%); 2nd decade: 39 patients 
(25.8%). Patients operated during the second decade (2010–
2019) were significantly older (62.2±8.3 vs. 59.3±7.0 years, 
P=0.036), had a significantly lower preoperative FEV1 
(71.5%±15.2% vs. 79.6%±19.0%, P=0.019) and showed a 
higher IMIG stage (stage III in 51.3% vs. 34.8%). 
Surgical details
Details of the surgical procedure are shown in Table 2. In all 
but one patient, EPP included a resection and reconstruction 
of the diaphragm and the pericardium (99.3%). A systematic 
lymphadenectomy was performed in 91.4% of all cases. 
MCR could be achieved in 146 patients (96.7%).
Outcome
Postoperative complications and the outcome after EPP 
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are presented in Table 3. Seven patients (4.6%) died within 
30 days after EPP. Death within 90 days after surgery 
occurred in 16 patients (10.6%).
The 1-, 2- and 3-year OS were 63.6%, 37.1% and 
22.5%, respectively and the median OS after EPP was 
18.5 months (95% CI: 1.1–90.5 months) (Figure 1). In 39 
patients who were operated after 2009, the median survival 
was increased to 22.0 months (95% CI: 0.8–112.2 months). 
However, no significant difference in the rate of major 
postoperative complications was found in patients operated 
during the first and during the second decade (36.6% 
vs. 43.6% respectively, P=0.71). The incidence of major 
postoperative morbidity as a composite outcome was 38.4% 
(Figure 2). Pleural empyema with or without BPF was the 
most common cause of major morbidity with an incidence 
of 23.2% and 11.3%, respectively, followed by chylothorax 
(6.6%) and postoperative bleeding requiring reoperation 
(6.6%). A diaphragmatic patch failure was encountered in 
8 patients (5.3%), resulting in a subsequent diaphragmatic 
hernia in 5 patients (3.3%). In 35.1% of all patients, a 
Table 1 Patients’ characteristics
Characteristic Cohort: n=151
Male gender 132 (87.4%)
Right sided 83 (55%)
Age at operation 60.0±7.4












Platinum based/pemetrexed 104 (68.9%)
Platinum based/gemcitabine 46 (30.5%)
Other 1 (0.7%)

















Partial remission 38 (36.9%)
Stable disease 39 (37.9%)



























a, information not available for all patients. BMI, body mass 
index; DLCO, diffusion capacity for carbon monoxide; FEV1, 
forced expiratory volume in 1 second; FVCex, forced vital 
capacity exhaled, IMIG, International Mesothelioma Interest 
Group; RECIST, response evaluation criteria in solid tumors.
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reoperation was necessary. Tracheotomy after prolonged 
weaning was performed in 5 patients (3.3%). A transfusion 
of one or more blood products and postoperative atrial 
fibrillation were the most common minor complication, 
occurring in 45.7% and 33.8% of all patients, respectively.
Discussion
In this present single-center study we retrospectively 
analyzed the outcomes of 151 patients with MPM 
undergoing EPP at the University Hospital Zurich between 
January 1999 and December 2019. Our main findings 
show a 30-day short-term mortality of 4.6% and a median 
survival after surgery of 18.5 months. The perioperative 
mortality matches previous findings in the literature. 
In two meta-analyses by Taioli et al. and Cao et al., 
Table 2 Type of surgery
Surgical characteristic: Cohort: n=151
Extrapleural pneumonectomy (EPP) 151 (100%)
Resection of diaphragm 150 (99.3%)
Resection of pericardium 150 (99.3%)
Lymphadenectomy 138 (91.4%)
Rib resection 1 (0.7%)
Table 3  Short- and long-term outcome
Outcome characteristic: Cohort: n=151
Duration of hospitalization (days) 17.3±11.3
In-hospital mortality 8 (5.3%)
30-day mortality 7 (4.6%)
90-day mortality 16 (10.6%)




Postoperative major morbidity 58 (38.4%)
Reoperation 53 (35.1%)
Pleural empyema 35 (23.2%)
Bronchopleural fistula 17 (11.3%)
Postoperative hemorrhage 10 (6.6%)
Chylothorax 10 (6.6%)
Diaphragmatic patch failure 8 (5.3%)
Diaphragmatic hernia 5 (3.3%)
Pulmonary embolism 4 (2.6%)
ARDS 2 (1.3%)
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Figure 1 Kaplan-Meier curve depicting overall survival after EPP 
in patients with MPM (n=151).
Figure 2 Major postoperative morbidity assessed as a composite 
outcome and occurred in 38.4% of all patients. Data given in 
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an increased perioperative mortality of 4.5 and 6.8%, 
respectively, was documented in patients undergoing 
EPP when compared to EPD. In our study cohort, major 
morbidity occurred in 38.4% and was most commonly 
caused by empyema. Empyema was treated according to 
our accelerated treatment concept with repeated radical 
surgical debridement of the pleural cavity, closure of BPF (if 
present), application of povidone-iodine soaked dressings, 
negative pressure wound therapy and systemic antibiotic 
therapy (21). The high rate of empyema and BPF has been 
previously described after EPP. It is hypothesized that a 
devascularized bronchial stump after parietal pleurectomy 
in combination with preceding chemotherapy may account 
for an increased rate of BPF in these patients (22,23). Atrial 
fibrillation was the most common minor complication, 
occurring in 33.8% of all patients, and has been previously 
reported in other cohorts (13,14,23,24). In relation to the 
high rate of perioperative major morbidity, the relatively 
low 30-day mortality demonstrates that complications after 
EPP can be successfully managed in experienced centers. 
In general, the center’s volume or case-load of patients 
plays an important role in morbidity and mortality after 
MPM surgery, as it has been demonstrated previously in an 
analysis of the STS general thoracic surgery database (25).
The median OS documented in previous studies assessing 
long-term outcomes after multimodality treatment with EPP 
varies between 12 and 22 months with a plateau commonly 
reached at about 18–22 months (26,27). In respect to the 
chosen surgical approach for MPM (EPP or EPD), the 
available data in the literature on OS are contradicting. While 
an analysis of the IASLC database showed an increased OS 
in patients with stage I undergoing EPP compared to EPD 
(40 vs. 23 months median survival) (28), other authors found 
no significant difference in overall survival (12,13) or even 
a significantly increased mortality in patients undergoing 
EPP (6,29). The only randomized controlled trial assessing 
the feasibility of a trimodal approach including induction 
chemotherapy, EPP, and postoperative hemithorax 
irradiation (MARS trial) had shown a limited OS after a 
trimodal treatment (14.4 vs. 19.5 months) (30). However, 
no valid conclusion could be drawn from the findings, since 
the trial lacked a sufficiently powered cohort and protocol 
compliance was inadequate (31,32). 
The role of EPP has also been described for selected 
patients with pleural dissemination of other pleural 
malignancies, such as thymomas, low-grade sarcomas, 
and rare tumors such as hemangioendothelioma (33-37). 
For patients with pleural dissemination of thymoma, an 
excellent survival of up to 76% has been reported after EPP 
within a multidisciplinary approach (34,35,38,39).
In a study by Nakamura et al., EPP offered better OS 
and progression-free survival than an isolated resection 
of pleural dissemination in patients with sufficient 
cardiopulmonary reserve (38). For sarcoma and other rare 
thoracic malignancies, EPP is mostly only performed as a 
salvage procedure in otherwise healthy patients where other 
therapeutic options are exhausted (35,36,40).
In consideration of the baseline characteristics in 
our documented cohort with almost 40% of all patients 
having IMIG stage IIIA or IIIB and a mean preoperative 
tumor volume of 294.6 cm3 (Table 1), the present median 
survival of 18.5 months in our patient cohort is thus 
considered consistent with the previously documented 
OS. In the subgroup of patients who were operated after 
2009, the median OS after EPP has further increased 
to 22.0 months. This increase is most probably multi-
factorial and is assumed to represent the experience with 
the procedure, the postoperative management, the patient 
selection, as well as improvements in oncological and radio-
oncological treatment after recurrence. This increase in OS 
is especially noteworthy since patients operated after 2010 
were in general older, had a lower preoperative FEV1 and 
higher IMIG stages. However, the rates of postoperative 
complications did not differ between patients operated 
during the first and the second decade. A significant 
amount of the patients in our cohort underwent adjuvant 
radiotherapy, including 16 patients who received adjuvant 
hemithoracic radiation in the SAKK 17/04 randomized 
trial. The trial concluded that hemithoracic radiotherapy 
after EPP would rather provide an additional treatment 
burden without offering a survival benefit and this subgroup 
may further have affected the OS of the cohort (19). Since 
the interpretation of older follow-up CTs may be highly 
variable due to the long retrospective nature of the study 
in patients with EPP who underwent radical resections, 
progression-free survival was not assessed in this analysis. 
For the preoperative selection of patients who may 
benefit from radical surgery in a multimodality concept, we 
nowadays only perform EPP or EPD in patients with an 
MMPS <3. In the past 20 years, EPP was performed in 6 
patients with an MMPS >2. However, these patients were 
operated before the implementation of the MMPS in 2015 
and the MMPS was retrospectively assessed during the 
process of its establishment.
In consideration of the increased perioperative morbidity 
after EPP for MPM and the high rates of local recurrence 
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despite MCR, the role of EPP has been controversially 
discussed and lung-preserving solutions have come to the 
fore. This way, the preservation of the affected lung may 
help to tolerate possible further treatment (10). Due to 
the vast heterogeneity in biological behavior and due to 
the presumably small effect size between EPP and EPD in 
respect to OS, a large randomized controlled trial would 
be required to identify the ideal surgical approach from 
an oncological standpoint. Considering the limited OS in 
most patients despite radical treatment, it is to be discussed 
whether an optimization in OS or in quality of life should 
be considered as primary endpoint. At our institution, 
we analyzed QoL (preoperatively, 6 weeks and 4 months 
postoperatively) of patients diagnosed with MPM undergoing 
a multimodality therapy approach including either EPP or 
EPD (manuscript submitted). Our results show a trend in 
favor of (E)PD regarding certain items in the patient’s QoL. 
Nevertheless, EPP was not associated with an overall greater 
deterioration of QoL, consequently this procedure should 
still be part of the multimodality therapy approach.
This trend towards the lung-sparing approach raises 
the question in which cases an EPP would still be justified. 
In our center, EPD is the primarily chosen approach for 
patients with MPM scheduled for surgical resection with 
the intent of MCR. This is reflected by the fact that only 
one fourth (n=39, 25.8%) of all EPP patients in our cohort 
were operated in the past 10 years. However, the standard 
preoperative assessment of chest wall or parenchymal 
infiltration by computed tomography (CT) and magnetic 
resonance imaging (MRI) does not always provide sufficient 
soft tissue resolution to rule out the necessity of an 
extensive resection, namely by EPP (41). The decision on 
the surgical approach may thus only be made upon surgical 
exploration. We therefore recommend that all patients 
scheduled for MCR undergo a preoperative assessment by 
spirometry and V/Q-scan to predict postoperative FEV1 
and determine whether the healthy lung offers sufficient 
quality and functional reserve to tolerate an EPP (27). Our 
present data confirm that despite recent trends towards 
EPD, EPP performed in an experienced center may still 
offer a reasonable approach in selected cases with large 
tumor burden and extensive involvement of the lung 
parenchyma, but good functional reserve of the non-
affected lung (6,10,42,43). As a single-center study it needs 
to be highlighted, that external validity may be limited 
and the findings may not be generalizable. Moreover, the 
institution’s experience is crucial to prevent and possibly 
also manage postoperative complications such as ARDS or 
post-pneumonectomy empyema (14). This also includes the 
anesthesiologic experience to avoid high intraoperative FiO2 
and barotrauma, both factors known to potentially trigger 
an ARDS after induction chemotherapy (6,14). 
Conclusions
According to the current guidelines, a multimodality 
approach including neoadjuvant chemotherapy and MCR 
is recommended for selected patients. The past decade has 
shown a trend towards lung-sparing strategy (EPD) in most 
centers. In this current retrospective analysis of 151 patients 
who underwent EPP in the past 20 years, the main findings 
demonstrate that EPP is feasible in patients including 
advanced stage mesothelioma with high tumor burden 
and/or extensive infiltration into the lung parenchyma. 
However, patients need to be informed about the elevated 
morbidity and mortality with this approach and it should 
only be performed in experienced centers. In patients with 
locally advanced MPM, we recommend an individualized 
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